| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 | 430 | 415 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 320 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 | 109 | 95 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % | 25 % | 21 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 | 18 | 15 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 | 53 | 42 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 | 10.17 | 7.99 |
Metropolis Healthcare
Metropolis Healthcare
471.70
-0.55
(-0.12%)
Market Cap
9,779.65 Cr
PE Ratio
57.84
Volume
1,07,705.00
Day High - Low
473.95 - 465.15
52W High-Low
565.75 - 397.08
Key Fundamentals
Market Cap
9,779.65 Cr
EPS
28.29
PE Ratio
57.84
PB Ratio
6.84
Book Value
69.09
EBITDA
318.10
Dividend Yield
0.00 %
Industry
Healthcare Services Sector
Healthcare Service Provider Return on Equity
10.90
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Metropolis Healthcare submitted its quarterly compliance certificate under SEBI regulations for Q4FY26, confirming proper handling of dematerialisation processes through its registrar MUFG Intime India.
Metropolis Healthcare reports strong Q4FY26 performance with ~23% YoY consolidated revenue growth, driven by TruHealth wellness and specialty testing segments across B2B and B2C channels.
Metropolis Healthcare completes 3:1 bonus share allotment on March 23, 2026, issuing 15,54,95,826 new equity shares with record date March 20, 2026. Paid-up share capital increases to INR 41,46,55,536.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,402.10 | #1 23,492.89 | 44.37 | #1 2,554.80 | 11.28 | #1 492 | -6.83 | 55.79 | |
1,022.55 | 10,521.70 | 65.51 | 699.70 | 23.06 | 144 | 22.38 | 69.46 | |
471.70 | #3 9,779.65 | #8 57.84 | #2 1,346.30 | #9 10.64 | #2 146 | #6 33.65 | 58.33 | |
389.05 | 6,192.33 | 46.23 | 702.20 | 20.80 | 91 | 47.37 | 53.52 | |
585.80 | 5,877.96 | 80.25 | 769.90 | 33.97 | 67 | 60.20 | 60.90 | |
622.75 | 2,020.12 | 24.86 | 742.70 | 16.70 | 78 | -21.13 | 58.09 | |
282.57 | 1,471.65 | 45.25 | 255.90 | 15.11 | 31 | 20.00 | 64.67 | |
645.95 | 1,262.39 | 20.68 | 147.80 | #1 134.60 | 19 | #1 520.00 | 58.63 | |
1,315.00 | 1,128.67 | #1 18.39 | 111.60 | 28.72 | 48 | 65.93 | 55.32 | |
269.15 | 856.18 | 29.51 | 1,170.80 | -18.47 | -134 | 101.06 | 44.22 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Equity & Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,078 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % | 48.89 % | 48.88 % | 48.87 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % | 12.52 % | 11.69 % | 10.77 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % | 33.10 % | 34.73 % | 35.46 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % | 3.69 % | 3.87 % | 4.02 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % | 1.80 % | 0.83 % | 0.89 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 | 47,846 | 46,670 | 48,488 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 4.13 | 1.43 | 1.57 | 2.56 | 1.86 | 1.02 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2021 |  Dividend | ₹ 8.00 /share | 17 Feb 2021 | 540.89 | 502.96 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 614.99 | 494.03 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 322.34 | 337.15 |
| 17 Nov 2023 | Dividend | ₹ 4.00 /share | 17 Nov 2023 | 368.06 | 401.71 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 524.58 | 522.89 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 529.78 | 528.15 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 427.23 | 439.44 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 423.70 | 428.08 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 504.75 | 513.93 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 484.70 | 523.23 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 488.30 | 501.11 |
| 11 Nov 2025 | Dividend | ₹ 4.00 /share | 11 Nov 2025 | 501.11 | 484.01 |
| 04 Feb 2026 | Quarterly Result Announcement | NA | 04 Feb 2026 | 450.80 | 476.08 |
| 20 Mar 2026 |  Bonus | 3:1 | 20 Mar 2026 | 454.70 | 456.29 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 days ago
5 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2026
Apr 07, 2026Business Update For Q4FY26Apr 03, 2026
Apr 03, 2026Closure of Trading WindowMar 31, 2026
Mar 31, 2026Announcement under Regulation 30 (LODR)-AllotmentMar 23, 2026
Mar 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2026
Mar 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2026
Mar 12, 2026Intimation Of Record Date For The Purpose Of Issuing Bonus Equity SharesMar 10, 2026
Mar 10, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 09, 2026
Mar 09, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 09, 2026
Mar 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Mar 02, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2026
Feb 07, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-RestructuringFeb 04, 2026
Feb 04, 2026Corporate Action-Board recommends Bonus IssueFeb 04, 2026
Feb 04, 2026Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 04, 2026
Feb 04, 2026Board Meeting Outcome for The Meeting Held Today (February 04 2026)Feb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2026
Jan 30, 2026Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025 And Issuance Of Bonus SharesJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 13, 2026
Jan 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 13, 2026
Jan 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026 Business Update For Q3FY26Jan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 31, 2025
Dec 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Nov 24, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On November 21 2025Nov 21, 2025
Nov 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Update On Schedule Of Earnings Conference Call For The Quarter And Half Year Ended September 30 2025Nov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Nov 04, 2025Corporate Action-Board approves DividendNov 04, 2025
Nov 04, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Nov 04, 2025Board Meeting Outcome for For The Meeting Held Today (November 04 2025)Nov 04, 2025
Nov 04, 2025Grant Of Stock BenefitsNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 And Declaration Of Interim Dividend If Any For The Financial Year 2025-26Oct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Business Update For Q2FY26Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Sep 18, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.33
ATR(14)
Less Volatile 18.38
STOCH(9,6)
Overbought 87.44
STOCH RSI(14)
Overbought 92.71
MACD(12,26)
Bullish 5.24
ADX(14)
Weak Trend 17.29
UO(9)
Bearish 62.61
ROC(12)
Uptrend And Accelerating 9.49
WillR(14)
Overbought -17.72
About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical...more
Listing Date
15 Apr, 2019(7 Years,
4 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
